7.2.2.13 (12beta,20R)-12-hydroxy-20,25-epoxydammarane-3,6-dione - 227622 7.2.2.13 (1R,2R,3aS,5aS,6aR,7aS,9R,11R,11aS,12aR,13aR,15aR)-2,3a,11,11a-tetrahydroxy-9,15a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)icosahydro-7aH,13aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxine-13a-carbaldehyde - 82196 7.2.2.13 (1R,2R,3aS,5aS,6aR,7aS,9S,11R,11aS,12aR,13aR,15aR)-3a,11,11a-trihydroxy-9-(hydroxymethyl)-15a-methyl-1-(5-oxo-2,5-dihydrofuran-3-yl)-2-(2-oxopropanoyl)icosahydro-7aH,13aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxine-13a-carbaldehyde - 82229 7.2.2.13 (1R,3aS,5aS,6aR,7aS,9R,11R,11aS,12aR,13aR,15aR)-13a-formyl-3a,11a-dihydroxy-9,15a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)icosahydro-1H,7aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxin-11-yl beta-D-glucopyranoside - 82048 7.2.2.13 (1R,3aS,5aS,6aR,7aS,9R,11R,11aS,12aR,13aR,15aR)-3a,11,11a-trihydroxy-9,15a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)icosahydro-7aH,13aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxine-13a-carbaldehyde - 82219 7.2.2.13 (1R,3aS,5aS,6aR,7aS,9S,11R,11aS,12aR,13aR,15aR)-3a,11,11a-trihydroxy-9-(hydroxymethyl)-15a-methyl-1-(5-oxo-2,5-dihydrofuran-3-yl)icosahydro-7aH,13aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxine-13a-carbaldehyde - 81942 7.2.2.13 (1S,3aR,3bR,12aR,14R)-10-fluoro-14-hydroxy-3a,3b,6,6,12a-pentamethyl-1-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,3a,3b,4,5a,6,7,12,12a,12b,13,14,14a-tetradecahydrocyclopenta[5,6]naphtho[2,1-b]carbazol-5(1H)-one - 227632 7.2.2.13 (1S,3aR,3bR,12aR,14R)-14-hydroxy-3a,3b,6,6,12a-pentamethyl-1-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,3a,3b,4,5a,6,7,12,12a,12b,13,14,14a-tetradecahydrocyclopenta[5,6]naphtho[2,1-b]carbazol-5(1H)-one - 227631 7.2.2.13 (1S,3aR,3bR,12aR,14R)-14-hydroxy-3a,3b,6,6,12a-pentamethyl-10-(trifluoromethoxy)-1-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,3a,3b,4,5a,6,7,12,12a,12b,13,14,14a-tetradecahydrocyclopenta[5,6]naphtho[2,1-b]carbazol-5(1H)-one - 227633 7.2.2.13 (20R)-20,25-epoxydammarane-3,6,12-trione - 227621 7.2.2.13 (3beta,12beta,20R)-12-hydroxy-3-phenoxy-20,25-epoxydammaran-6-one - 227613 7.2.2.13 (3beta,12beta,20R)-12-hydroxy-3-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)oxy]-20,25-epoxydammaran-6-one - 227615 7.2.2.13 (3beta,12beta,20R)-12-hydroxy-3-[4-(trifluoromethoxy)phenoxy]-20,25-epoxydammaran-6-one - 227612 7.2.2.13 (3beta,12beta,20R)-3-(ethenyloxy)-12-hydroxy-20,25-epoxydammaran-6-one - 227611 7.2.2.13 (3beta,12beta,20R)-3-ethoxy-12-hydroxy-20,25-epoxydammaran-6-one - 227610 7.2.2.13 (3E,5beta,15beta,16beta)-16-(acetyloxy)-3-(hydroxyimino)-8-methyl-14,15-epoxybufa-20,22-dienolide - 227634 7.2.2.13 (3E,5beta,15beta,16beta)-16-(acetyloxy)-3-(methoxyimino)-8-methyl-14,15-epoxybufa-20,22-dienolide - 227635 7.2.2.13 (3E,5beta,15beta,16beta)-16-(acetyloxy)-3-[(2-aminoethoxy)imino]-8-methyl-14,15-epoxybufa-20,22-dienolide most potent inhibitor 227636 7.2.2.13 (5aR,7R,8S,10aR,10bR)-7-hydroxy-1,1,5a,10a,10b-pentamethyl-8-[(2R)-2,6,6-trimethyloxan-2-yl]hexadecahydrocyclopenta[5,6]naphtho[2,1-c]azepine-3,12-dione - 227626 7.2.2.13 (5aR,8S,10aR,10bR,12R)-12-hydroxy-1,1,5a,10a,10b-pentamethyl-8-[(2R)-2,6,6-trimethyloxan-2-yl]tetradecahydro-1H-cyclopenta[5,6]naphtho[2,1-c]oxepine-3,7-dione - 227623 7.2.2.13 (5aR,8S,10aR,10bR,12S)-12-hydroxy-1,1,5a,10a,10b-pentamethyl-8-[(2R)-2,6,6-trimethyloxan-2-yl]tetradecahydro-1H-cyclopenta[5,6]naphtho[2,1-c]oxepine-3,7-dione - 227624 7.2.2.13 (6alpha,12beta,20R)-12-hydroxy-6-[(prop-2-en-1-yl)oxy]-20,25-epoxydammaran-3-one - 227617 7.2.2.13 (6alpha,12beta,20R)-6,12-bis(benzyloxy)-20,25-epoxydammaran-3-one - 227618 7.2.2.13 (6alpha,12beta,20R)-6,12-bis[(prop-2-en-1-yl)oxy]-20,25-epoxydammaran-3-one - 227616 7.2.2.13 (6alpha,12beta,20R)-6-(benzyloxy)-12-hydroxy-20,25-epoxydammaran-3-one - 227619 7.2.2.13 (6alpha,20R)-6-hydroxy-20,25-epoxydammarane-3,12-dione - 227620 7.2.2.13 1,8,9-trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one i.e. wedelolactone, inhibitor of kidney Na+K+-ATPase and ligand for the central benzodiazepine receptor 65291 7.2.2.13 1-chloro-2,4-dinitrobenzene inhibition of the transport activity of the Na-K pump 182 7.2.2.13 12,20-dihydroxydammar-24-en-3-yl 2-O-D-glucopyranosyl-D-glucopyranoside - 146908 7.2.2.13 12,20-dihydroxydammar-24-en-3-yl D-glucopyranoside - 72944 7.2.2.13 19-hydroxy-2''-oxovoruscharin i.e. UNBS1450, a trans-trans-cis cardiotonic steroid 163537 7.2.2.13 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one ODQ, inhibition of SNP-induced pump stimulation 135682 7.2.2.13 2,3-dihydroxy-6H-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-6-one inhibitor of kidney Na+K+-ATPase and ligand for the central benzodiazepine receptor 65359 7.2.2.13 2,8,9-trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one inhibitor of kidney Na+K+-ATPase and ligand for the central benzodiazepine receptor 65364 7.2.2.13 2,9-dihydroxy-3,8-dimethoxy-6H-[1]benzofuro[3,2-c]chromen-6-one inhibitor of kidney Na+K+-ATPase and ligand for the central benzodiazepine receptor 65365 7.2.2.13 2-aminoethyl-methanethiosulfonate inhibition of mutants F323C, P333C, E334C, G335C, I322C, G326C and A330C 123191 7.2.2.13 3,8,9-trihydroxy-2-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one inhibitor of kidney Na+K+-ATPase and ligand for the central benzodiazepine receptor 65433 7.2.2.13 3-oxo-panaxatriol - 232903 7.2.2.13 3-[(2-O-D-glucopyranosyl-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-20-yl D-glucopyranoside - 146921 7.2.2.13 3-[(3S,3aS,4R,5aR,6S,9aR,9bS)-4-hydroxy-6,9a,9b-trimethyl-8-oxo-3-[(2R)-2,6,6-trimethyloxan-2-yl]dodecahydro-1H-cyclopenta[a]naphthalen-6-yl]propanoic acid - 227629 7.2.2.13 4,7-diacetoxy-14-hydroxydolast-1(15),8-diene - 75615 7.2.2.13 4-acetoxy-9,14-dihydroxydolast-1(15),7-diene - 151922 7.2.2.13 4-[(1R,3aS,5aS,6aR,7aS,9R,11R,11aS,12aR,13aR,15R,15aS)-3a,11,11a,15-tetrahydroxy-13a-(hydroxymethyl)-9,15a-dimethylicosahydro-1H,7aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxin-1-yl]furan-2(5H)-one - 82192 7.2.2.13 4-[(1R,3aS,5aS,6aR,7aS,9S,11R,11aS,12aR,13aR,15aR)-3a,11,11a-trihydroxy-9,13a-bis(hydroxymethyl)-15a-methylicosahydro-1H,7aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxin-1-yl]furan-2(5H)-one - 82409 7.2.2.13 4-[(1R,3aS,5aS,6aR,7aS,9S,11R,11aS,12aR,13aR,15R,15aS)-3a,11,11a,15-tetrahydroxy-9,13a-bis(hydroxymethyl)-15a-methylicosahydro-1H,7aH-cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxin-1-yl]furan-2(5H)-one - 82429 7.2.2.13 5-hydroxydecanoate presence of 5 mM ATP, inhibitory above 1 mM. Presence of 0.05 mM ATP, inhibitory above 0.25 mM. No effect on ouabain-sensitiviy of the enzyme 144080 7.2.2.13 6-oxo-panaxatriol - 232902 7.2.2.13 8-methoxycoumestrol inhibits the isozyme alpha1beta1 Na,K-ATPase, mechanism, overview 83764 7.2.2.13 A-769662 inhibits the Na+-K+-ATPase transport activity and cell surface abundance in L6 cells, which is independent of AMP kinase activation, overview 14440 7.2.2.13 alpha2-adrenergic agonists negative modulator 135679 7.2.2.13 astragaloside III from dried roots of Astragalus membraneceus or var. mongholicus 162345 7.2.2.13 ATP competitive inhibitor of K+-phosphatase activity 4 7.2.2.13 AuCl4- - 144591 7.2.2.13 Aurovertin - 10913 7.2.2.13 bafilomycin - 32152 7.2.2.13 BAY-K8644 a calcium channel agonist, the effect is blocked by a phosphatidylinositol-3 kinase inhibitor wortmannin 83763 7.2.2.13 benzyltriethylammonium chloride inhibition of pump current is dependent on membrane potential 62771 7.2.2.13 beta-acetyldigoxin - 83766 7.2.2.13 bradykinin negative modulator 466 7.2.2.13 bufalin inhibition of the enzyme, enhancement of the acidification of the late endosome, alteration in membrane traffic 17624 7.2.2.13 bufalin from dried venom of Bufo gargarizans or Bufo bufo melanostictus 17624 7.2.2.13 bufalin - 17624 7.2.2.13 Ca2+ enzyme from anterior intestine is 5-fold more sensitive than enzymes from pyloric caeca and posterior intestine 15 7.2.2.13 Ca2+ CaCl2 up to 300 microM does not affect Na+/K+-ATPase activity, but CaCl2 above 1 mM inhibits the activity 15 7.2.2.13 chlorpromazine - 727 7.2.2.13 cholic acid from dried bile of Ursus arctos or Selenarctos thibetanus 783 7.2.2.13 cinobufagin - 232905 7.2.2.13 cinobufotalin 27.5% inhibition at 0.01 mM 206678 7.2.2.13 cyclosporin A diminishs induction of alpha1 protein in activated lymphocytes 1044 7.2.2.13 dammar-24-ene-3,12,20-triol - 146909 7.2.2.13 dammar-24-ene-3,6,12,20-tetrol - 146906 7.2.2.13 dansylcysteinyl-mercuric chloride - 103871 7.2.2.13 digitoxigenin - 11231 7.2.2.13 digitoxin - 13679 7.2.2.13 digoxin - 5369 7.2.2.13 dihydroouabain - 151924 7.2.2.13 diphenyl diselenide activity is restored by DTT 4678 7.2.2.13 DMSO - 896 7.2.2.13 dopamine negative modulator 242 7.2.2.13 EGTA - 173 7.2.2.13 endobain E - 151923 7.2.2.13 endothelin negative modulator 6076 7.2.2.13 epicatechin - 1161 7.2.2.13 epicatechin-3-gallate solubilization of the Na+,K+-ATPase with a nonionic detergent reduces sensitivity to epigallocatechin-3-gallate 4992 7.2.2.13 epigallocatechin - 2229 7.2.2.13 epigallocatechin-3-gallate noncompetitive with respect to ATP, reduces the affinity for vanadate, shifts the equilibrium of E1P and E2P toward E1P, and reduces the rate of the E1P to E2P transition 2607 7.2.2.13 epinephrine 0.5 mM epinephrine added for 20 min, decreases the activity of the enzyme by around 50%. Treatment with Rp-cAMP, indomethacin, PP2, SB202190, and PD98059 completely abrogate the effect of epinephrine 1141 7.2.2.13 Ethacrynic acid - 1046 7.2.2.13 ethanol inhibits the enzyme in Golgi membranes of cerebellar neurons leading to potentiation of GABAergic transmission at Golgi cell-to-granule cell synapses throughan increase in Golgi cell excitability 69 7.2.2.13 ethanol - 69 7.2.2.13 ethylester of glutathione inhibition of the transport activity of the Na-K pump 135680 7.2.2.13 ethylmercurithiosalicylate - 93368 7.2.2.13 fenoldopam induces inhibition of Na+ ?K+-ATPase activity in HK-2 cells. Ouabain protects against the cyclic adenosine monophosphate accumulation and Na+ ?K+-ATPase inhibition induced by the D1 receptor agonist fenoldopam in HK-2 cells. Chronic ouabain treatment decreases the protein and mRNA expression levels of the D1 receptor and increases the basal phosphorylation of the D1 receptor in HK-2 cells 163539 7.2.2.13 foliandrin - 163538 7.2.2.13 genistein tyrosine kinase inhibitor, block phosphorylation of alpha-subunit of the Na+,K+-ATPase 377 7.2.2.13 ginsenoside Rh2 from dried roots of Panax ginseng or Panax notoginseng 78769 7.2.2.13 glibenclamide - 11130 7.2.2.13 glyburide presence of 5 mM ATP, slightly stimulating up to 1 mM, inhibitory above. Presence of 0.05 mM ATP, stimulating at least up to 3 mM 14374 7.2.2.13 glycyrrhizin from roots of Glycyrrhiza uralensis , Glycyrrhiza inflata, or Glycyrrhiza glabra 4646 7.2.2.13 herbimycin A tyrosine kinase inhibitor, block phosphorylation of alpha-subunit of the Na+,K+-ATPase 135678 7.2.2.13 isovaleric acid isovaleric acid injection significantly inhibits Na+,K+-ATPase activity by 25% in cerebral cortex of rats 2 or 24 h after administration, while pre-treatment of rats with creatine completely prevents the inhibitory effects of isovaleric acid on Na+,K+-ATPase 13186 7.2.2.13 istaroxime - 227972 7.2.2.13 jujuboside B from mature seeds of Ziziphus jujube var. spinosa 162233 7.2.2.13 L-homocysteine inhibitory effect is reversed by alanine 305 7.2.2.13 L-phenylalanine - 104 7.2.2.13 lauric acid presence of 5 mM ATP, inhibitory above 0.25 mM. Presence of 0.05 mM ATP, stimulating up to 0.3 mM, inhibitory above 959 7.2.2.13 lavendustin A tyrosine kinase inhibitor, block phosphorylation of alpha-subunit of the Na+,K+-ATPase 35174 7.2.2.13 Lyn kinase Lyn kinase directly binds to the Na+,K+-ATPase alpha3 subunit for regulation of activity 36452 7.2.2.13 m-trifluoromethyl-diphenyl diselenide i.e. (m-CF3–C6H4Se)2, activity is restored by DTT 83767 7.2.2.13 marinobufagenin - 135683 7.2.2.13 methyl 3-[(3S,3aS,4R,5aR,6R,7R,9aR,9bS)-4-hydroxy-7-(2-hydroxypropan-2-yl)-6,9a,9b-trimethyl-8-oxo-3-[(2R)-2,6,6-trimethyloxan-2-yl]dodecahydro-1H-cyclopenta[a]naphthalen-6-yl]propanoate - 227627 7.2.2.13 methyl 3-[(3S,3aS,4R,5aR,6R,7S,9aR,9bS)-4-hydroxy-6,9a,9b-trimethyl-8-oxo-7-(prop-2-en-1-yl)-3-[(2R)-2,6,6-trimethyloxan-2-yl]dodecahydro-1H-cyclopenta[a]naphthalen-6-yl]propanoate - 227628 7.2.2.13 methyl 3-[(3S,3aS,4R,5aR,6S,9aR,9bS)-4-hydroxy-6,9a,9b-trimethyl-8-oxo-3-[(2R)-2,6,6-trimethyloxan-2-yl]dodecahydro-1H-cyclopenta[a]naphthalen-6-yl]propanoate - 227630 7.2.2.13 methyldigoxin - 83765 7.2.2.13 Mg2+ IC50: 0.0008 mM; IC50: 0.0012 mM; IC50: 0.012 mM 6 7.2.2.13 Mg2+ considerable inhibition of enzyme activity is seen above 5 mM Mg2+ 6 7.2.2.13 monosodium glutamate selenofuranoside therapy is able to prevent the inhibition of the enzyme activity in the hippocampus but not in the brain cortex 100940 7.2.2.13 additional information decrease in extracellular pH inhibits Na+-K+ pump activity 2 7.2.2.13 additional information not inhibitory: NH4+. At elevated concentrations of NH4+, enzyme is fully active and K+ cannot displace NH4+ from its exclusive binding sites 2 7.2.2.13 additional information molecular docking and modelling, and inhibitory potencies of steroid-like compounds from Chinese medicinal products, used for promoting the blood circulation, with Na+,K+-ATPase, overview 2 7.2.2.13 additional information odoroside A and ouabain potently reduce NF-kappaB-inducible de novo protein synthesis, largely due to its ability to block Na+-dependent transport of amino acids across the plasma membrane, but not to interfering with the translation machinery 2 7.2.2.13 additional information physical training is effective against Na+,K+-ATPase enzyme activity inhibition, while fluid percussion injury induces a decrease in Na+,K+-ATPase activity in the ipsilateral cerebral cortex of sedentary animals 2 7.2.2.13 additional information ETB receptor inhibits Na+-K+ ATPase activity by facilitating extracellular Ca2+ entry and Ca2+ release from endoplasmic reticulum 2 7.2.2.13 additional information inhibitory potencies of cardenolide glycosides, isolated from the roots of Pergularia tomentosa, on Na+,K+-ATPase activity 2 7.2.2.13 additional information cardiac glycosides are efficient inhibitors of the Na+,K+-ATPase 2 7.2.2.13 additional information enzyme activity is inhibited by excess ATP 2 7.2.2.13 additional information spermine has a negligible effect (less than 10%) on enzyme activity 2 7.2.2.13 MTSET [2-(trimethylammonium)ethyl]methanethiosulphonate bromide, inhibits mutants G803C, V805C 135681 7.2.2.13 Na+ 25% inhibition at 80 mmol/l 59 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A1 0% decreases in expression of human alpha subunit in 293T cells 62772 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A1 - 62772 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A2 20% decreases in expression of human alpha subunit in 293T cells 62773 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A2 - 62773 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A3 20% decreases in expression of human alpha subunit in 293T cells 62774 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A3 - 62774 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A4 40% decreases in expression of human alpha subunit in 293T cells 62775 7.2.2.13 Na/K ATPase-alpha1-specific siRNA A4 - 62775 7.2.2.13 Na2CO3 inactivation 20429 7.2.2.13 O-[(3beta,12beta,20R)-12-hydroxy-6-oxo-20,25-epoxydammaran-3-yl] O-methyl 2-imidothiodicarbonate - 227614 7.2.2.13 odoroside A i.e. 3beta-O-(beta-D-diginosyl)-14-hydroxy-5beta,14beta-card-20(22)-enolide, isolated from the stems and twigs of Nerum oleander, inhibits the enzyme's ATPase activity 83770 7.2.2.13 oleandrin - 41267 7.2.2.13 oleandrin oleandrin treatment results in selective inhibition of human cancer cell growth but not rodent cell proliferation, which corresponds to the relative level of Na,K-ATPase alpha3 subunit protein expression. A correlation is observed between the ratio of alpha3 to alpha1 isoforms and the level of oleandrin uptake during inhibition of cell growth and initiation of cell death, the higher the alpha3 expression relative to alpha1 expression, the more sensitive the cell is to treatment with oleandrin 41267 7.2.2.13 oleanolic acid - 2975 7.2.2.13 oleanolic acid from whole plant of Prunella vulgaris with dried flowers 2975 7.2.2.13 oleic acid - 380 7.2.2.13 oligomycin inhibits (Na+,K+)-ATPase reaction and Na+-ATPase reaction, has little effect on the K+-phosphatase reaction and can stimulate the ADP/ATP exchange reaction 2150 7.2.2.13 oligomycin not completely inhibits but decreases the rate of turnover of transport and of the hydrolysis reaction. Oligomycin affects the extracellular side of the system, Na+ on the cytoplasmic side of the system is necessary for the effect, oligomycin decreases the rate of transition from the Na+ form to the K+ form of the enzyme, but has no effect on the rate of the reverse reaction 2150 7.2.2.13 Omeprazole inhibit mutants G803C, T804C, V805C 2976 7.2.2.13 orthovanadate - 1328 7.2.2.13 orthovanadate up to 67% inhibition in absence of NH4+ 1328 7.2.2.13 orthovanadate up to 87% inhibition 1328 7.2.2.13 orthovanadate up to 75% inhibition at 0.05 mM 1328 7.2.2.13 orthovanadate about 44% inhibition at 3 mM 1328 7.2.2.13 orthovanadate increasing orthovanadate concentrations from 0.0001 mM to 1 mM inhibit total ATPase activity by around 75% 1328 7.2.2.13 ouabagenin - 75606 7.2.2.13 Ouabain - 866 7.2.2.13 Ouabain g-strophanthin 866 7.2.2.13 Ouabain enzyme from anterior intestine is ten-fold more sensitive than enzymes from pyloric caeca and posterior intestine 866 7.2.2.13 Ouabain interaction is dependent on the conformation and phosphorylation state of the protein 866 7.2.2.13 Ouabain inhibition of enzyme, enhancement of the acidification of the late endosome 866 7.2.2.13 Ouabain up to 67% inhibition in absence of NH4+ 866 7.2.2.13 Ouabain up to 87% inhibition 866 7.2.2.13 Ouabain ouabain does not affect TNF-alpha-induced mRNA expression but inhibits TNF-alpha-induced protein expression 866 7.2.2.13 Ouabain complete inhibition at 0.001 mM 866 7.2.2.13 Ouabain ouabain triggers an apoptotic cascade that involves NCX and CaMKII as a downstream effector. Ouabain simultaneously activates an antiapoptotic cascade involving PI3K/AKT which is however, insufficient to completely repress apoptosis. The NCX inhibitor KB-R7943 and by the CaMKII inhibitors, KN93 and AIP prevent ouabain-induced apoptosis without affecting inotropy. Ouabain produces in the cat at 25 nM a 43% decrease in cell viability due to apoptosis and necrosis 866 7.2.2.13 Ouabain ouabain triggers an apoptotic cascade that involves NCX and CaMKII as a downstream effector. Ouabain simultaneously activates an antiapoptotic cascade involving PI3K/AKT which is however, insufficient to completely repress apoptosis.The NCX inhibitor KB-R7943 and by the CaMKII inhibitors, KN93 and AIP prevent ouabain-induced apoptosis without affecting inotropy 866 7.2.2.13 Ouabain ouabain triggers an apoptotic cascade that involves NCX and CaMKII as a downstream effector. Ouabain simultaneously activates an antiapoptotic cascade involving PI3K/AKT which is however, insufficient to completely repress apoptosis. The NCX inhibitor KB-R7943 and by the CaMKII inhibitors, KN93 and AIP prevent ouabain-induced apoptosis without affecting inotropy. Ouabain produces in the rat at 0.002 mM a 43% decrease in cell viability due to apoptosis and necrosis 866 7.2.2.13 Ouabain a cardiac glycoside derived from Strophanthus gratus, ouabain is deeply inserted into the transmembrane domain with the lactone ring very close to the bound K+. Low-affinity ouabain-bound state due to antagonism between ouabain and K+. The closure of the binding cavity confers a high affinity, homology model for the high affinity state, structures, overview. Binding of sugar moiety and steroid core, overveiw 866 7.2.2.13 Ouabain ouabain up to 1 mM decreases silkworm ATPase activity to 42% of the maximal ATPase activity in presence of 10 mM NaCl and 30 mM KCl 866 7.2.2.13 Ouabain Na+/K+-ATPase specific inhibitor 866 7.2.2.13 Ouabain 73% inhibition at 3 mM 866 7.2.2.13 Ouabain about 50% inhibition at 3 mM, ouabain inhibition increases about 80% in the presence of NH4+ with a 3fold lower KI value 866 7.2.2.13 Ouabain 55% inhibition at 0.02 mM 866 7.2.2.13 Ouabain 6.1% inhibition at 0.01 mM 866 7.2.2.13 Ouabain about 30% inhibition at 2 mM 866 7.2.2.13 Ouabain specific inhibitor 866 7.2.2.13 Ouabain about 70% inhibition at 3 mM 866 7.2.2.13 Ouabain 76.4% residual activity at 3 mM 866 7.2.2.13 oubain - 2784 7.2.2.13 oubain the IC50 value is higher in neonates than in children 2784 7.2.2.13 oubain K+ completely abolishes oubain binding to alpha1-beta1 isoenzymes. Residual oubain binding is still observed at high K+ concentrations for alpha2-beta1 and alpha3-beta1 complexes 2784 7.2.2.13 oubain two apparently different oubain binding sites 2784 7.2.2.13 oubain K+ protects against inhibition, probably due to phosphorylating effect 2784 7.2.2.13 oubain quantitative aspects of the interaction between oubain and the enzyme in vitro 2784 7.2.2.13 oubain half-maximal inhibition at 0.1 mM 2784 7.2.2.13 p-chloro-diphenyl diselenide i.e. (p-Cl–C6H4Se)2, activity is restored by DTT 83768 7.2.2.13 p-methoxyl-diphenyl diselenide i.e. (p-CH3O–C6H4Se)2, activity is restored by DTT 83769 7.2.2.13 palytoxin - 23140 7.2.2.13 palytoxin mild, non-toxic, exposures to the Na+/K+-ATPase inhibitor palytoxin synergistically sensitizes the vulnerability of neurons to normally non-toxic concentrations of domoic acid, leaving NMDA receptor-mediated excitotoxic response unaltered. Palytoxin causes a voltage-sensitive Na+ channel-independent increase in intracellular Na+. Enhancement of the excitotoxic response to domoic acid by palytoxin is time-dependent and is not affected by gene expression inhibitors 23140 7.2.2.13 panaxatriol - 232901 7.2.2.13 Pb2+ inhibitory effect of Pb2+ on the transport cycle of the Na+,K+-ATPase, overview. Pb2+ inhibits cycling of the enzyme, but it does not affect cytoplasmic Na+ binding and release of Na+ ions at the extracellular side at concentrations below 0.010 mM 139 7.2.2.13 PCMB - 78 7.2.2.13 perillyl alcohol a monoterpene, inhibits Na/K-ATPase, non-competitive inhibition for Na+ and K+ and an uncompetitive inhibition for ATP in brain and kidney 6011 7.2.2.13 perillyl alcohol a monoterpene, inhibits Na/K-ATPase showing a noncompetitive inhibition profile to Na+ and K+ and an uncompetitive inhibition towards ATP. The generated electrochemical gradient is essential for a number of other cellular functions 6011 7.2.2.13 polygalacic acid from dried roots of Platycodon grandiflorum 162253 7.2.2.13 PP1 Src kinase inhibitor 6878 7.2.2.13 prostaglandin E2 PGE2 913 7.2.2.13 prostaglandin E2 - 913 7.2.2.13 Prostaglandins negative modulator 31116 7.2.2.13 putrescine - 155 7.2.2.13 putrescine putrescine inhibits (Na+, K+)-ATPase phosphorylation and activity in juvenile and adult shrimp gill 155 7.2.2.13 reduced glutathione extracellular and, or intracellular, inhibition of the transport activity of the Na-K pump 593 7.2.2.13 rottlerin - 4993 7.2.2.13 saikosaponin A from dried roots of Bupleurum chinense or Bupleurum scorzonerifolium 162299 7.2.2.13 sarsasapogenin from dried roots of Anemarrhena asphodeloides 162206 7.2.2.13 spermidine - 148 7.2.2.13 spermidine spermidine inhibits (Na+, K+)-ATPase phosphorylation and activity in juvenile and adult shrimp gill 148 7.2.2.13 spermine - 197 7.2.2.13 strophanthidin tyrosine kinase inhibitor, block phosphorylation of alpha-subunit of the Na+,K+-ATPase 24464 7.2.2.13 strophanthidin 29.6% inhibition at 0.01 mM 24464 7.2.2.13 strophantidine - 123192 7.2.2.13 superoxide - 3110 7.2.2.13 suramin potent inhibitor, acts on the inside surface of the sodium pump 704 7.2.2.13 tetraethylammonium chloride inhibition of pump current is independent on membrane potential 30913 7.2.2.13 thapsigargin - 2240 7.2.2.13 theophylline - 1221 7.2.2.13 Tumor necrosis factor alpha TNF-alpha, TNF-alpha affects the Na+-K+ pump via PGE2-dependent pathways 2773 7.2.2.13 ursolic acid from whole plant of Prunella vulgaris with dried flowers 2291 7.2.2.13 uzarigenin - 232904 7.2.2.13 vanadate - 233 7.2.2.13 vanadate 20fold less sensitive to vanadate than alpha1 and 3; 20 times more sensitive to vanadate than alpha2 233 7.2.2.13 vanadate epigallocatechin-3-gallate reduces the affinity for vanadate, shifts the equilibrium of E1P and E2P toward E1P, and reduces the rate of the E1P to E2P transition 233 7.2.2.13 Yes kinase regulator of the Na+,K+-ATPase activity 62770 7.2.2.13 [Au(2,2'-bipyridine)Cl2]+ - 206680 7.2.2.13 [Au(dimethylsulfoxide)2Cl2]+ - 206679 7.2.2.13 [PdCl(dien)]+ noncompetitive, affinity for binding in decreasing order: [PdCl4]2-, [PdCl(dien)]+, [PdCl(Me4dien)]+. Addition of L-cysteine or glutathoione before exposure to Pd(II) complexes prevents inhibition 69483 7.2.2.13 [PdCl(Me4dien)]+ noncompetitive, affinity for binding in decreasing order: [PdCl4]2-, [PdCl(dien)]+, [PdCl(Me4dien)]+. Addition of L-cysteine or glutathoione before exposure to Pd(II) complexes prevents inhibition 69316 7.2.2.13 [PdCl4]2- noncompetitive, affinity for binding in decreasing order: [PdCl4]2-, [PdCl(dien)]+, [PdCl(Me4dien)]+. Addition of L-cysteine or glutathoione before exposure to Pd(II) complexes prevents inhibition 69315